Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All molnupiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Efficacy of Molnupiravir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study).

Gentile et al., medRxiv, doi:10.1101/2024.09.09.24313305, SAVALO
Sep 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 4% Improvement Relative Risk Hospitalization 26% Hospitalization, ICU, morta.. 65% Molnupiravir for COVID-19  SAVALO  EARLY TREATMENT Is early treatment with molnupiravir beneficial for COVID-19? PSM retrospective 1,382 patients in Italy (January - December 2022) Lower progression with molnupiravir (p=0.013) c19early.org Gentile et al., medRxiv, September 2024 Favorsmolnupiravir Favorscontrol 0 0.5 1 1.5 2+
PSM retrospective case-control study with 1,382 SARS-CoV-2 positive outpatients in Italy, showing lower risk for a composite outcome of hospitalization, ICU admission, or death with molnupiravir, but no significant difference for mortality or hospitalization.
Potential risks include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-10. Multiple analyses have identified variants potentially created by molnupiravir11-14.
risk of death, 4.2% lower, OR 0.96, p = 0.79, treatment 146, control 1,236, case control OR, propensity score matching.
risk of hospitalization, 25.6% lower, OR 0.74, p = 0.74, treatment 146, control 1,236, case control OR, propensity score matching.
hospitalization, ICU, mortality, 64.7% lower, OR 0.35, p = 0.01, treatment 146, control 1,236, case control OR, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gentile et al., 9 Sep 2024, retrospective, Italy, preprint, 19 authors, study period 1 January, 2022 - 31 December, 2022, SAVALO trial. Contact: riccardo.scotto@unina.it, ri.scotto@gmail.com.
This PaperMolnupiravirAll
Efficacy of Molnupiravir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study).
Ivan Gentile, M.D Riccardo Scotto, Maria Michela Scirocco, Francesco Di Brizzi, Federica Cuccurullo, Maria Silvitelli, Luigi Ametrano, Francesco Antimo Alfe', Daria Pietroluongo, Irene Irace, Mariarosaria Chiariello, Noemi De Felice, Simone Severino, Giulio Viceconte, Nicola Schiano Moriello, Alberto Enrico Maraolo, Antonio Riccardo Buonomo, Agnese Giaccone
doi:10.1101/2024.09.09.24313305
Introduction Molnupiravir (MNP) is an orally administered prodrug which prevents disease progression in patients at high risk for severe COVID-19. We conducted a real-life case-control study on a cohort of outpatients, with Omicron SARS-CoV-2 infection to assess the e^ectiveness of MNP in reducing the occurrence of hospital admission, admission in intensive care unit (ICU) and death at day 28. Materials and methods Cases were enrolled among SARS-CoV-2 positive subjects that sought medical care during the first five days of symptoms from January 1st, 2022, to December 31st, 2022, and received MNP. Control participants were selected from a regional database among those who tested positive during the study period and did not receive antiviral treatment for SARS-CoV-2. Results 1382 patients were included (cases: 146, controls: 1236). Vaccinated patients showed lower risk of mortality and composite outcome (at least one among hospital admission, admission in ICU and allcause death) compared to unvaccinated ones (0.6% vs 7.8%, p<0.001 and 2% vs 7.8%, p=0.001 respectively). After full-matching propensity score, MNP-treated subjects showed a lower incidence of composite outcome, while no e^ect was observed on the single outcomes. In the subgroup analysis according to the vaccination status, MNP proved e^ective in preventing all the outcomes among unvaccinated patients, while showed to reduce the risk of ICU admission both in vaccinated and unvaccinated patients. Conclusions Treatment with MNP proved e^ective in reducing the risk of composite outcome among outpatients with SARS-CoV-2 infection. The beneficial e^ect of MNP treatment in reducing progression is more pronounced in unvaccinated patients.
Competing interests Prof. IVAN GENTILE reports personal fees from MSD, AbbVie, Gilead, Pfizer, GSK, SOBI, Nordic/Infecto Pharm, Angelini and Abbott, as well as departmental grants from Gilead and support for attending a meeting from Janssen, outside the submitted work. All other authors have no competing interests to declare Declaration of generative AI and AI-assisted technologies in the writing process During the preparation of this work the authors used Microsoft© Copilot, powered by Chat-GPT IV, after the completion of the first draft, in order to improve readability and the English grammar of the paper. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article
References
Baek, Park, Won, Park, Kim, Propensity score matching: a conceptual review for radiology researchers, Korean J Radiol, doi:10.3348/kjr.2015.16.2.286
Bajema, Berry, Streja, Rajeevan, Li et al., E^ectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes, Annals of internal medicine, doi:10.7326/m22-3565
Bernal, Da Silva, Musungaie, Kovalchuk, Gonzalez et al., Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, The New England journal of medicine, doi:10.1056/NEJMoa2116044
Butler, Hobbs, Gbinigie, Rahman, Hayward et al., Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial, Lancet, doi:10.1016/s0140-6736(22)02597-1
Dibello, Raziano, Liu, Puenpatom, Peebles et al., Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review, Infectious diseases and therapy, doi:10.1007/s40121-024-00976-5
Eikenboom, Cessie, Waernbaum, Groenwold, De Boer, Quality of Conduct and Reporting of Propensity Score Methods in Studies Investigating the E^ectiveness of Antimicrobial Therapy, Open Forum Infect Dis, doi:ofac110.10.1093/ofid/ofac110
Gandhi, Hirsch, Treating Acute Covid-19 -Final Chapters Still Unwritten, The New England journal of medicine, doi:10.1056/NEJMe2402224
Green, Stuart, Examining moderation analyses in propensity score methods: application to depression and substance use, J Consult Clin Psychol, doi:10.1037/a0036515
Hansen, Klopfer, Optimal Full Matching and Related Designs via Network Flows, Journal of Computational and Graphical Statistics, doi:10.1198/106186006X137047
Hu, Jia, Zhao, Fu, Zhang et al., Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019-positive patients, Clinical microbiology and infection : the o^icial publication of the European Society of Clinical Microbiology and Infectious Diseases, doi:10.1016/j.cmi.2023.03.017
Li, Wang, Chen, Lu, Song et al., Estimands in observational studies: Some considerations beyond ICH E9 (R1), Pharm Stat, doi:10.1002/pst.2196
Najjar-Debbiny, Gronich, Weber, Khoury, Amar et al., E^ectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis, Clinical infectious diseases : an o^icial publication of the Infectious Diseases Society of America, doi:10.1093/cid/ciac781
Nguyen, Collins, Spence, Daurès, Devereaux et al., Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance, BMC Med Res Methodol, doi:10.1186/s12874-017-0338-0
Paraskevis, Gkova, Mellou, Gerolymatos, Psalida et al., Real-world E^ectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk, The Journal of infectious diseases, doi:10.1093/infdis/jiad324
Razonable, Ganesh, Bierle, Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19, Mayo Clin Proc, doi:10.1016/j.mayocp.2021.11.017
Snowden, Rose, Mortimer, Implementation of G-computation on a simulated data set: demonstration of a causal inference technique, American journal of epidemiology, doi:10.1093/aje/kwq472
Thomas, Li, Pencina, Using Propensity Score Methods to Create Target Populations in Observational Clinical Research, Jama, doi:10.1001/jama.2019.21558
Whitley, Molnupiravir -A Step toward Orally Bioavailable Therapies for Covid-19, The New England journal of medicine, doi:10.1056/NEJMe2117814
Wong, Au, Lau, Lau, Cowling et al., Real-world e^ectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study, The Lancet Infectious diseases, doi:10.1016/s1473-3099(22)00507-2
Yip, Lui, Lai, Wong, Tse et al., Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19), Clinical infectious diseases : an o^icial publication of the Infectious Diseases Society of America, doi:10.1093/cid/ciac687
{ 'institution': [{'name': 'medRxiv'}], 'indexed': {'date-parts': [[2024, 9, 10]], 'date-time': '2024-09-10T00:26:43Z', 'timestamp': 1725928003144}, 'posted': {'date-parts': [[2024, 9, 9]]}, 'group-title': 'Infectious Diseases (except HIV/AIDS)', 'reference-count': 0, 'publisher': 'Cold Spring Harbor Laboratory', 'license': [ { 'start': { 'date-parts': [[2024, 9, 9]], 'date-time': '2024-09-09T00:00:00Z', 'timestamp': 1725840000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2024, 9, 9]]}, 'abstract': '<jats:p>Introduction Molnupiravir (MNP) is an orally administered prodrug which prevents ' 'disease progression in patients at high risk for severe COVID-19. We conducted a real-life ' 'case-control study on a cohort of outpatients, with Omicron SARS-CoV-2 infection to assess ' 'the effectiveness of MNP in reducing the occurrence of hospital admission, admission in ' 'intensive care unit (ICU) and death at day 28. Materials and methods Cases were enrolled ' 'among SARS-CoV-2 positive subjects that sought medical care during the first five days of ' 'symptoms from January 1st, 2022, to December 31st, 2022, and received MNP. Control ' 'participants were selected from a regional database among those who tested positive during ' 'the study period and did not receive antiviral treatment for SARS-CoV-2. Results 1382 ' 'patients were included (cases: 146, controls: 1236). Vaccinated patients showed lower risk of ' 'mortality and composite outcome (at least one among hospital admission, admission in ICU and ' 'all-cause death) compared to unvaccinated ones (0.6% vs 7.8%, p&lt;0.001 and 2% vs 7.8%, ' 'p=0.001 respectively). After full-matching propensity score, MNP-treated subjects showed a ' 'lower incidence of composite outcome, while no effect was observed on the single outcomes. In ' 'the subgroup analysis according to the vaccination status, MNP proved effective in preventing ' 'all the outcomes among unvaccinated patients, while showed to reduce the risk of ICU ' 'admission both in vaccinated and unvaccinated patients. Conclusions Treatment with MNP proved ' 'effective in reducing the risk of composite outcome among outpatients with SARS-CoV-2 ' 'infection. The beneficial effect of MNP treatment in reducing progression is more pronounced ' 'in unvaccinated patients.</jats:p>', 'DOI': '10.1101/2024.09.09.24313305', 'type': 'posted-content', 'created': {'date-parts': [[2024, 9, 9]], 'date-time': '2024-09-09T22:55:15Z', 'timestamp': 1725922515000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Efficacy of Molnupiravir in reducing the risk of severe outcome in patients with SARS-CoV-2 ' 'infection: a real-life full-matched case-control study (SAVALO Study).', 'prefix': '10.1101', 'author': [ {'given': 'Ivan', 'family': 'Gentile', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-0178-2986', 'authenticated-orcid': False, 'given': 'Riccardo', 'family': 'Scotto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maria Michela', 'family': 'Scirocco', 'sequence': 'additional', 'affiliation': []}, {'given': 'Francesco', 'family': 'Di Brizzi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Federica', 'family': 'Cuccurullo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maria', 'family': 'Silvitelli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Luigi', 'family': 'Ametrano', 'sequence': 'additional', 'affiliation': []}, {'given': 'Francesco Antimo', 'family': "Alfe'", 'sequence': 'additional', 'affiliation': []}, {'given': 'Daria', 'family': 'Pietroluongo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Irene', 'family': 'Irace', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mariarosaria', 'family': 'Chiariello', 'sequence': 'additional', 'affiliation': []}, {'given': 'Noemi', 'family': 'De Felice', 'sequence': 'additional', 'affiliation': []}, {'given': 'Simone', 'family': 'Severino', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-3989-2520', 'authenticated-orcid': False, 'given': 'Giulio', 'family': 'Viceconte', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-8474-4776', 'authenticated-orcid': False, 'given': 'Nicola', 'family': 'Schiano Moriello', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alberto Enrico', 'family': 'Maraolo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Antonio Riccardo', 'family': 'Buonomo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Agnese', 'family': 'Giaccone', 'sequence': 'additional', 'affiliation': []}, {'name': 'Federico II COVID Team', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2024.09.09.24313305', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 9, 9]], 'date-time': '2024-09-09T22:55:16Z', 'timestamp': 1725922516000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2024.09.09.24313305'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 9, 9]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.1101/2024.09.09.24313305', 'relation': {}, 'subject': [], 'published': {'date-parts': [[2024, 9, 9]]}, 'subtype': 'preprint'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit